A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Clinical trial NCT04672356 · COMPLETED
Trial details
- NCT number
- NCT04672356
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-25
- Primary completion
- 2023-01-01
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.